Drug intelligence / Profile preview

PF-08049820

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-08049820 is an orally available, investigational small molecule being developed by Pfizer for the treatment of atopic dermatitis. It is classified as an anti-inflammatory and skin disorder therapy, but its precise mechanism of action has not been disclosed. As of early 2025, it is a new molecular entity in Phase 1 clinical trials for atopic dermatitis. The drug is currently being evaluated in healthy adult volunteers to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics[2][3][4][5].

Other names: PF 08049820PF08049820PF-08049820

Targets

STAT6 (Signal Transducer and Activator of Transcription 6)

Beyond the preview

Go deeper on PF-08049820.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-08049820.

Explore the full profile